Avacopan with standard care for kidney disease caused by vasculitis
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests if adding avacopan to standard treatments (rituximab or cyclophosphamide plus steroids) helps patients with severe kidney inflammation from a type of vasculitis. It may offer a new option for preserving kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new or returning flare of ANCA-associated vasculitis affecting your kidneys (called rapidly progressive glomerulonephritis).
- Your kidney function is severely reduced (eGFR between 0 and 29 mL/min).
- You have active kidney disease shown by blood in urine and high protein in urine.
- You are starting standard therapy with rituximab or cyclophosphamide plus steroids for this flare.
- You are willing to have a kidney biopsy either before or within 4 weeks of starting the study.
- Women who can become pregnant must use effective birth control during the study and for 12 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two strategies for people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have stable disease but whose ANCA blood test has become positive again. The goal is to see whether waiting and monitoring closely works as well as giving a pre-emptive dose of rituximab to prevent a flare.
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
This trial tests a new treatment called CT1192 for a type of blood vessel inflammation called ANCA-associated vasculitis. It is for people whose standard treatments have not worked or whose disease has come back. The goal is to see if CT1192 is safe and helps control the disease.
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
Hear when a new ANCA-Associated Vasculitis (AAV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.